Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from PFE

Pfizer Stock Outlook: Is Wall Street Bullish or Bearish?

Despite Pfizer trailing behind the broader market over the past year, Wall Street analysts remain moderately bullish about the stock's potential.

Barchart

This Dividend Stock Has Plunged Ahead of Trump’s Inauguration. Here Are 3 Reasons Investors Should Still Buy It.

For savvy investors, Pfizer could be an undervalued stock to buy here.

Barchart

3 Pharmaceutical Stocks Addressing Global Health Challenges

With the recent rise of diseases, pharmaceutical companies are pushing boundaries in medicine, from life-saving treatments to pioneering global healthcare solutions. Hence, investing in established pharmaceutical stocks, Pfizer (PFE), Johnson & Johnson (JNJ), and Merck & Co. (MRK) presents a compelling opportunity to capitalize for the long term. Read more.

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

What to Expect From Pfizer's Next Quarterly Earnings Report

Pfizer is poised to announce its fourth-quarter results next month, and analysts predict a significant growth in the company’s bottom-line figure.

Barchart

Pfizer: 4 Reasons to Buy This Stock

Pharmaceutical giant Pfizer Inc. (NYSE: PFE) stock is trading back down near its pandemic lows. Every time it attempts to climb over the $30 mark, something ca

MarketBeat

3 High-Yield Dividend Stocks to Secure Before Year-End

Dividend-paying stocks provide investors with consistent income in turbulent markets, especially as payouts grow over time. Therefore, investors might consider adding dividend stocks, Pfizer (PFE), United Parcel Service (UPS), and Enterprise Products Partners (EPD) before year-end. Read more….

StockNews.com

3 Cheap Stocks With High Analyst Price Targets for 2024

Cheap stocks are worth considering now due to expected interest rate cuts, potential market rebounds, and substantial upside in growing industries. Hence, stocks like Pfizer (PFE), Micron Technology (MU), and Precision Drilling (PDS), with high analyst price targets for 2024, are smart portfolio additions now. Read on.

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

3 High-Yield Dividend Stocks to Boost Your Portfolio in 2024

With the economy showing mixed growth signals and changing federal policies, buying high-yielding dividend stocks could be a great choice for your portfolio. Thus, investors can invest in high-yield dividend stocks Pfizer (PFE), Altria Group (MO), and VICI Properties (VICI) to boost their portfolio. Read more….

StockNews.com

Pfizer Stock: Is PFE Underperforming the Healthcare Sector?

Despite Pfizer's underperformance relative to the healthcare sector, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

3 Undervalued Healthcare Stocks With Upside Potential

The healthcare industry thrives due to novel drug pipeline discoveries, AI integration to streamline processes and technological advancements. So, investing in undervalued healthcare stocks with upside potential, Pfizer (PFE), Cigna Group (CI), and Centene Corp (CNC), could be a wise idea. Keep reading….

StockNews.com

3 Healthcare Stocks Leading the Fight Against Global Diseases

As chronic and infectious diseases continue to rise, the demand for advanced healthcare solutions grows. Hence, investing in established healthcare stocks, Pfizer (PFE), Merck & Co (MRK), and AbbVie (ABBV), presents a compelling opportunity to capitalize on the sector’s landscape. Read on….

StockNews.com

Thursday's Unusual Options Activity Reveals 3 Promising Long-Term Investments

Thursday's trading session revealed 33 call options with unusually high activity and boasting expiration dates of 365 days or more. Three have emerged as promising long-term investments from this diverse pool of potential opportunities.

Barchart

3 Defensive Stocks to Buy as Market Volatility Rises

Amid current economic uncertainties and market volatility, investing in defensive stocks appears as an ideal strategy for portfolio protection. Thus, quality defensive stocks Johnson & Johnson (JNJ), Pfizer (PFE), and Genie Energy (GNE) could be ideal portfolio additions as market volatility rises. Continue reading.

StockNews.com

3 Healthcare Stocks for Long-Term Stability and Growth

With the rise of chronic diseases, technological advances and innovative drug pipelines are driving significant growth in the healthcare industry. Hence, investors may find long-term stability and exciting opportunities by adding stocks, Johnson & Johnson (JNJ), Pfizer (PFE), and Cigna Group (CI), to their portfolios. Read more….

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Is This High-Yield Dividend Stock a Buy After Earnings?

This pharmaceutical giant's Q3 numbers came in ahead of Street estimates.

StockNews.com

3 High-Yield Dividend Stocks to Buy for Steady Passive Income

In times of market uncertainties, high-dividend yield stocks are ideal investment choices for their qualities like stable passive income, protection against inflation, and price appreciation. Thus, investors could consider fundamentally sound, high dividend yield stocks Verizon Communications (VZ), Pfizer (PFE), and Enterprise Products Partners (EPD) for steady passive income. Read…

Barchart

Are Wall Street Analysts Predicting Pfizer Stock Will Climb or Sink?

Despite Pfizer’s underperformance relative to the broader market over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

What to Expect From Pfizer's Q3 2024 Earnings Report

Pfizer is expected to release its fiscal third-quarter earnings later this month, and analysts project a triple-digit profit growth.

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Should You Follow Activist Investors Into This High-Yield Dividend Stock?

This dividend stock is now on the radar of activist investors, with Starboard eyeing a possible management shakeup.

Kiplinger

Stock Market Today: Markets Slip on Hot Inflation Print, Layoff News

Economic data continues to complicate expectations for Federal Reserve rate cuts.

Barchart

Is This Overlooked Dividend Stock Yielding Almost 6% a Good Turnaround Play?

Despite its dividend yield of nearly 6%, Pfizer stock has failed to win over investors and is in the red YTD. Can the stock finally stage a turnaround, as activist investor Starboard Value has reportedly taken a stake in the company?

Barchart

2 Covered Call Ideas on Pfizer Stock

Today, we’re looking at two covered call examples on Pfizer stock. The first step to finding our covered call candidates is to use the Stock Scanner with the following parameters:

Barchart

How to Buy PFE For a 6% Discount, or Achieve a 23% Annual Return

Selling cash secured puts on stocks an investor is happy to take ownership of is a great way to generate some extra income.

StockNews.com

3 High-Dividend Pharma Blue Chips That Are on Sale Right Now

With the Federal Reserve potentially cutting interest rates for the first time in over four years, uncertainty looms in the market. Amid this backdrop, it could be wise to scoop up the shares of fundamentally sound pharma stocks like AbbVie (ABBV), Novartis (NVS), and Pfizer (PFE), which are not just…

StockNews.com

3 Healthcare Stocks With High Analyst Price Targets

Recent innovations, successful trials, and increased research and development spending in the healthcare sector further boost the sector’s appeal today. Given this momentum, investors might consider investing in stocks with high analyst price targets, such as Pfizer (PFE), Biogen (BIIB), and BioMarin Pharmaceutical (BMRN). Read on….

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.